Grifols/$GRFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ticker
$GRFS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
23,800
ISIN
US3984384087
Website
Grifols Metrics
BasicAdvanced
$7.3B
26.25
$0.33
0.93
-
Price and volume
Market cap
$7.3B
Beta
0.93
52-week high
$9.57
52-week low
$5.79
Average daily volume
737K
Financial strength
Current ratio
2.599
Quick ratio
0.942
Long term debt to equity
113.214
Total debt to equity
121.139
Dividend payout ratio (TTM)
0.49%
Interest coverage (TTM)
2.29%
Profitability
EBITDA (TTM)
1,946.975
Gross margin (TTM)
39.39%
Net profit margin (TTM)
2.65%
Operating margin (TTM)
18.59%
Effective tax rate (TTM)
44.76%
Revenue per employee (TTM)
$362,340
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
3.45%
Valuation
Price to earnings (TTM)
26.252
Price to revenue (TTM)
0.693
Price to book
1.11
Price to tangible book (TTM)
-1.12
Price to free cash flow (TTM)
6.36
Free cash flow yield (TTM)
15.72%
Free cash flow per share (TTM)
138.05%
Growth
Revenue change (TTM)
10.76%
3-year revenue growth (CAGR)
13.70%
10-year revenue growth (CAGR)
7.84%
10-year earnings per share growth (CAGR)
-8.57%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Bulls say / Bears say
Grifols reported a 179% increase in net profit for Q1 2025, reaching €60 million, driven by a 7.4% rise in net revenue to €1.79 billion, primarily due to strong performance in its plasma-derived medicine business. (reuters.com)
Moody's upgraded Grifols' credit rating from B3 to B2 with a positive outlook, recognizing the company's improved financial health and recovery from previous challenges. (cincodias.elpais.com)
Grifols is expanding its presence in Egypt, a strategic market, by planning to double its donation centers by 2025 and establish a plasma plant in Cairo, aiming to strengthen its global footprint. (cincodias.elpais.com)
Grifols' stock has experienced significant volatility, with a 40.6% decline in 2024, raising concerns about its stability and investor confidence. (alphacubator.com)
The company's debt-to-equity ratio stands at 1.18, indicating a high level of leverage that could pose financial risks if not managed effectively. (barchart.com)
Grifols faces competition from recombinant versions of its hemophilia products and emerging anti-FcRn therapies, which could erode its market share in the immunoglobulin sector. (morningstar.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
GlobeNewsWire·2 weeks ago
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
Business Wire·4 weeks ago
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
Reuters·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $7.3B as of June 27, 2025.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 26.25 as of June 27, 2025.
Does Grifols stock pay dividends?
No, Grifols (GRFS) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Grifols dividend payment date?
Grifols (GRFS) stock does not pay dividends to its shareholders.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.